| Not Yet Recruiting | Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer NCT07528768 | AntiCancer Research Jamaica | Phase 2 |
| Recruiting | Saci Nivo Rela for TNBC NCT06963905 | Yale University | Phase 1 / Phase 2 |
| Recruiting | Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) NCT07011654 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy i NCT06851299 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Active Not Recruiting | Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast NCT06027268 | Wake Forest University Health Sciences | Phase 2 |
| Unknown | Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Canc NCT05746728 | Huihua Xiong | Phase 1 / Phase 2 |
| Recruiting | A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer NCT05570253 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | TIP in Patients Affected by Metastatic TNBC NCT05831553 | Fondazione per la Medicina Personalizzata | — |
| Active Not Recruiting | A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer NCT05227664 | Akeso | Phase 2 |
| Withdrawn | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for NCT05008510 | Veru Inc. | Phase 2 |
| Active Not Recruiting | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors NCT05101096 | Gilead Sciences | Phase 1 / Phase 2 |
| Terminated | Olinvacimab With Pembrolizumab in Patients With mTNBC NCT04986852 | PharmAbcine | Phase 2 |
| Unknown | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer NCT04739670 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Active Not Recruiting | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received NCT04454437 | Gilead Sciences | Phase 2 |
| Withdrawn | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer NCT04149444 | AHS Cancer Control Alberta | Phase 2 |
| Completed | Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer NCT04111510 | Yale University | Phase 2 |
| Suspended | Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Pr NCT04250818 | Texas Tech University Health Sciences Center, El Paso | — |
| Completed | Leflunomide in Previously Treated Metastatic Triple Negative Cancers NCT03709446 | Joseph Sparano | Phase 1 / Phase 2 |
| Unknown | Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer NCT05089643 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer NCT03577743 | Assiut University | Phase 2 |
| Completed | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer Wi NCT03256344 | Amgen | Phase 1 |
| Active Not Recruiting | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. NCT03330847 | AstraZeneca | Phase 2 |
| Completed | S 81694 Plus Paclitaxel in Metastatic Breast Cancer NCT03411161 | Institut de Recherches Internationales Servier | Phase 1 / Phase 2 |
| Completed | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC NCT03004183 | The Methodist Hospital Research Institute | Phase 2 |
| Completed | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer NCT03121352 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer NCT03055312 | Sun Yat-sen University | Phase 3 |
| Completed | L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Pat NCT02834403 | The Methodist Hospital Research Institute | Phase 1 / Phase 2 |
| Completed | Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative NCT02555657 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast NCT02158507 | University of Alabama at Birmingham | N/A |
| Withdrawn | Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors NCT01936961 | Western Regional Medical Center | N/A |
| Completed | Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer NCT01238952 | Nippon Kayaku Co., Ltd. | Phase 1 |